


Meseclazone

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 29053-27-8 |
| Formula: | C ₁₁ H ₁₀ ClNO ₃ |
| Molecular Weight: | 239.65 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|---------------|---|
| Description | Meseclazone has anti-inflammatory, analgesic, and antipyretic activity. Meseclazone shows inhibitory potency of secondary phase ADP aggregation. |
| Targets(IC50) | Others,AChR,P2Y Receptor |
| In vivo | Intravenous administration of Meseclazone, along with other nonsteroidal anti-inflammatory drugs (NSAIDs), has been found to cause a dose-dependent reduction in bronchoconstriction. This leads to a sequence of efficacy in decreasing order as follows: isoproterenol \approx indomethacin > fenoprofen > tolmetin > aspirin > naproxen \approx ibuprofen > phenylbutazone > diflunisal > Meseclazone > 5-CSA. Additionally, Meseclazone demonstrates the ability to inhibit collagen-induced platelet aggregation 1 and 4 hours post oral administration[1][2]. |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 4.1728 mL | 20.8638 mL | 41.7275 mL |
| 5 mM | 0.8346 mL | 4.1728 mL | 8.3455 mL |
| 10 mM | 0.4173 mL | 2.0864 mL | 4.1728 mL |
| 50 mM | 0.0835 mL | 0.4173 mL | 0.8346 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Diamantis W, et al. Meseclazone, 5-chlorosalicylic acid and acetylsalicylic acid. Comparison of their effects on in vitro and ex vivo platelet aggregation. *Thromb Haemost.* 1978 Aug 31;40(1):24-36.

Diamantis W, et al. Antagonism by meseclazone and other nonsteroidal anti-inflammatory drugs of bradykinin-induced bronchospasm. *Pharmacology.* 1982;24(4):243-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481